Author

R. K. Ma

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

P. Sethupathy· 3 shared K. Vakili· 2 shared M. Kanke· 2 shared A. B. Francisco· 1 shared A. Emili· 1 shared A. J. Shumway· 1 shared A. Karki· 1 shared A. P. Massa· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

P. Sethupathy

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma

R. K. Ma, P.-Y. Tsai, A. R. Farghli, A. J. Shumway, M. Kanke, J. D. Gordan, T. Gujral, K. Vakili, M. Nukaya, L. Noetzli, S. Ronnekleiv-Kelly, W. Broom, J. Barrow, P. Sethupathy

This paper identifies LINC00473 as a downstream mediator of DNAJB1-PRKACA fusion in fibrolamellar carcinoma, showing it promotes tumor growth and alters mitochondrial function.

bioRxiv · Jun 2, 2023Cancer Biology

DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling

S. S. Kim, I. Kycia, M. Karski, R. K. Ma, E. A. Bordt, J. Kwan, A. Karki, E. Winter, R. G. Aktas, Y. Wu, A. Emili, D. E. Bauer, P. Sethupathy, K. Vakili

The paper engineers a DNAJB1-PRKACA fusion in HEK293T cells to study its oncogenic effects, finding LINC00473 overexpression dependent on PKA signaling.

bioRxiv · Aug 11, 2021Cancer Biology

Hotspots of aberrant enhancer activity in fibrolamellar carcinoma reveal molecular mechanisms of oncogenesis and intrinsic drug resistance

T. A. Dinh, R. Sritharan, F. D. Smith, A. B. Francisco, R. K. Ma, R. P. Bunaciu, M. Kanke, C. G. Danko, A. P. Massa, J. D. Scott, P. Sethupathy

This study identifies aberrant enhancer activity in fibrolamellar carcinoma, revealing molecular mechanisms of oncogenesis and drug resistance, and suggests new therapeutic targets.

bioRxiv · Jan 18, 2020 · PreprintCancer Biology